文献速递乳房整形与再造美容整形

乳房增大成形术后的乳腺癌:病例对照研究

Breast Cancer following Augmentation Mammaplasty: A Case-Control Study.
PubMed 文献 · Plast Reconstr Surg · 2018-01-01

该机构病例对照研究纳入2000至2013年接受乳腺癌治疗的既往乳房增大成形术患者48例及倾向匹配随机对照302例,回顾性分析数据。结果显示增大组可触及病灶更小(1.6 cm vs 2.3 cm,p<0.001),筛查钼靶检出比例更低(77.8% vs 90.7%,p=0.010),更常行切除活检(20.5% vs 4.4%,p<0.001),乳房切除术率更高(74.5% vs 57.0%),保乳治疗率更低(25.5% vs 43%,p=0.023)。

要点

  • 增大组可触及病灶尺寸小于对照组(1.6 cm vs 2.3 cm,p<0.001)。
  • 增大组筛查钼靶检出病灶比例低于对照组(77.8% vs 90.7%,p=0.010)。
  • 增大组乳房切除术率高于对照组(74.5% vs 57.0%),保乳治疗率更低(25.5% vs 43%,p=0.023)。

核心结论

  • 增大患者可触及乳腺癌病灶尺寸更小,但筛查钼靶检出可能性低于对照组。
  • 增大乳腺癌患者疾病分期与对照组相当,更常接受乳房切除术而非肿块切除术。
  • 硅胶与盐水假体、胸肌下或腺体下放置对乳腺影像、活检方式和手术干预的影响相当。

研究设计与样本

  • 机构病例对照研究,纳入2000至2013年接受乳腺癌治疗的既往乳房增大成形术患者48例,倾向匹配随机对照302例,回顾性分析数据。
  • 证据等级:治疗性,III级。

主要发现

  • 增大组可触及病灶尺寸为1.6 cm,对照组为2.3 cm(p<0.001)。
  • 增大组筛查钼靶检出病灶比例为77.8%,对照组为90.7%(p=0.010)。
  • 增大组切除活检比例为20.5%,对照组为4.4%(p<0.001);影像引导空心针活检比例增大组为77.3%,对照组为95.3%(p<0.001)。
  • 增大组更早分期接近但未达统计学显著性(p=0.073)。
  • 增大组乳房切除术率为74.5%,对照组为57.0%;保乳治疗率增大组为25.5%,对照组为43%(p=0.023)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to determine whether augmentation mammaplasty, implant type, and implant location affect breast cancer detection, stage, and treatment. METHODS: An institutional case-control study was performed of patients with prior breast augmentation undergoing breast cancer treatment from 2000 to 2013. Controls were propensity matched and randomized, and data were retrospectively reviewed. RESULTS: Forty-eight cases and 302 controls were analyzed. Palpable lesions were detected at a smaller size in augmentation patients (1.6 cm versus 2.3 cm; p < 0.001). Fewer lesions in augmented patients were detected by screening mammography (77.8 percent of cases versus 90.7 percent of controls; p = 0.010). Patients with implants were more likely to undergo an excisional biopsy for diagnosis (20.5 percent versus 4.4 percent; p < 0.001), rather than image-guided core needle biopsy (77.3 percent versus 95.3 percent; p < 0.001). Earlier staging in augmented patients approached but did not reach statistical significance (p = 0.073). Augmented patients had higher mastectomy rates (74.5 percent versus 57.0 percent) and lower rates of breast-conservation therapy (25.5 percent versus 43 percent; p = 0.023). Neither implant fill type nor anatomic location affected method of diagnosis, stage, or treatment. CONCLUSIONS: Palpable detection of breast cancer is more likely at a smaller size in augmented patients, yet it is less likely on screening mammography than in controls. Augmentation breast cancer patients have a comparable disease stage and are more likely to undergo mastectomy rather than lumpectomy. Both silicone and saline implants, whether placed submuscularly or subglandularly, have comparable effects on breast imaging, biopsy modality, and surgical intervention. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Sosin M, Devulapalli C, Fehring C, et al. Breast Cancer following Augmentation Mammaplasty: A Case-Control Study. Plast Reconstr Surg. 2018. PMID: 29595718. doi:10.1097/PRS.0000000000004196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。